Vacation Resorts: Artisans and Travel in Mexico
Develop Your Domain Names
TriMark Publications Announces the TriMark Cancer Biomarkers Conference 2008 in New York City on June 16th
New York (PRWEB) June 2, 2008 -- TriMark Publications (http://www.trimarkpublications.com/conferences/), a global leader in biotechnology, healthcare and life sciences publishing, announces the TriMark Cancer Biomarkers Conference 2008 entitled:
?Cancer Biomarkers Development and Clinical Use?
The Conference will be a gathering of global companies leading the way in cancer biomarkers research and technology and will include presentations from industry experts such as:
Keynote Speaker Martin Fleisher, Ph.D.
Chair, Dept. of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center discussing:
"Current Recommendations for Cancer Assays"
? What is a biomarker and how is it used?
? Validating biomarkers for clinical use.
? Biomarkers as prognostic indicators of cancer recurrence.
? Biomarkers as surrogate endpoints for monitoring therapy.
Maher Albitar, M.D.
Director of Hematopathology at Nichols Institute, Quest Diagnostics, Inc. discussing:
?Plasma-Based Assays in Hematologic Diseases: New Paradigm in Clinical Testing?
? Why plasma is enriched by tumor-specific DNA, RNA and proteins?
? Why hematologic disease?
? What assays are currently best performed using plasma?
? How plasma is used to determine tumor load?
Peter Collins
Business Development Director, DxS Ltd. discussing:
?A K-RAS Companion Diagnostic for Vectibix?
? Amgen?s Vectibix (panitumumab) is one of several new cancer drugs currently in the market targeting the EGFR pathway. Recent clinical data has established that the 40% of colorectal tumors that carry a mutated K-RAS gene show little or no response to these therapies.
? DxS has developed and commercialized a companion diagnostic that detects the K-RAS mutations, to support the sale of Vectibix.
? This presentation will outline the development and approval of the product and also demonstrate a successful model for drug and diagnostic company partnerships.
Harry Rittenhouse, Ph.D.
Senior Director Cancer Program, Gen-Probe, Inc. discussing:
?How Genetics and Molecular Assays Will Change the Diagnosis and Management of Prostate Cancer?
? Most highly over-expressed gene in prostate cancer.
? PCA3 molecular urine test independent mechanism from PSA blood test.
? Early studies show a high potential for PCA3 to complement PSA testing for prostate cancer management.
? TMPRSS2 is a prostate-specific gene turned on in the presence of androgen.
? ETS family of genes.
? TMPRSS2:ETS gene fusions.
W. Jeffrey Allard, Ph.D.
Vice President, Clinical Affairs & Business Development, Fujirebio, Inc. discussing:
"Evaluation of Multiple Biomarker Assays to Estimate Risk of Ovarian Cancer in Patients Presenting with a Pelvic Mass"
? Pelvic mass and the dilemma of appropriate triage.
? Current practice and guidelines.
? Pilot studies.
? FDI03 pivotal trial.
? Clinical implementation of multi-biomarker algorithm.
Herbert Fritsche, Ph.D.
Professor and Chief, Clinical Chemistry; Chairman, Scientific Advisory Board, MD Anderson Cancer Center discussing:
"Bringing New Cancer Assay Technologies into the Lab"
? Many new diagnostic tests for cancer diagnosis and clinical management of patients are on the horizon and will soon be ready for implementation in routine patient care.
? Clinical acceptance of new cancer diagnostics is based on the level of proof for the clinical utility of the new test.
? Laboratory acceptance requires FDA clearance , if the test is commercialized in a "kit" format, and "adequate" reimbursement by Medicare and third party reimbursers.
? New rules from the FDA will impact on the commercialization of new diagnostics currently performed under CLIA regulations.
Keith McCormick
Director, Sales & Marketing, AviaraDx, Inc. discussing:
"New Biomarkers for Breast Cancer Risk Stratification - H/I and MGI"
? H/I (HoxB13:IL17BR Index) and MGI (Molecular Grade Index) independently evaluate distinct biological pathways.
? H/I is a two-gene ratio that stratifies ER-positive breast cancer into low or high risk of recurrence and is predictive of benefit from endocrine therapy.
? MGI is a five-gene index that provides quantitative and objective molecular assessment of tumor grade and proliferation status, stratifies breast cancers in low or high risk of recurrence, and identifies tumors like to be responsive to chemotherapy.
Richard Bender, M.D., FACP
Vice President and Chief Medical Officer, Agendia, Inc. discussing:
?Using Gene Expression Assays to Guide Therapy in Breast Cancer Patients?
? Understanding the methodology used to develop gene signatures for breast cancer prognosis.
? Comparison of the commercially available assays emphasizing their strengths and weaknesses.
? Understanding how these assays are used in clinical practice.
Eric Fung, Ph.D.
Vice President and CSO, Vermillion, Inc. discussing:
"Development of High-Value Diagnostic Assays in Ovarian Cancer and Peripheral Arterial Disease"
? Study design strategies for biomarker discovery.
? Pitfalls in statistical analysis for genomics and proteomics.
? Novel biomarkers for ovarian tumor triage and peripheral arterial disease.
? Risk stratification in patient management.
Anthony Shuber, Ph.D.
Chief Technical Officer, Predictive Biosciences, Inc. discussing:
"Utilizing Urinary Protein Biomarkers for Cancer Management"
? The clinical dilemma facing non-invasive biomarker assays.
? The value of non-invasive biomarkers assays.
? Working within the existing clinical environment.
? Making ?good? biomarkers ?great?.
Walt Carney, Ph.D.
Head, Siemens Medical Solutions Diagnostics, Oncogene Science Biomarker Group discussing:
"Monitoring Circulating HER-2/neu Levels in MBC Patients Treated with HER-2/neu Inhibitors"
? Linking circulating biomarkers in treatment of metastatic breast cancer.
? The rise and fall of serum HER-2/neu levels parallel the clinical course of breast cancer.
? Integrating serum HER-2/neu DX with management of metastatic breast cancer.
Kaiser J. Aziz, Ph.D., FACB, FACS
Director, KJ Biomedical Consulting, LLC discussing:
"Biomarkers: Discovery, Development and Clinical Applications"
? Development of biomarkers.
? Clinical study design.
? Product review.
? FDA?s quality system requirements.
? Risk management and quality monitoring.
The Conference will be held on Monday, June 16, 2008 at the Yale Club of New York City located at 50 Vanderbilt Avenue in New York City. Registration details at http://www.trimarkpublications.com/conferences/.
Registration Fees for the Conference:
? Standard Registration Fee is $395.
? At-the-Door Fee $500 on June 16, 2008 (subject to seating availability).
Register at http://www.trimarkpublications.com/conferences/
About TriMark Publications, LLC
TriMark Publications is a global leader in biotechnology, healthcare and life sciences publishing. For more information, please visit http://www.trimarkpublications.com/conferences/.
Important Notice
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
Contact
TriMark Publications, LLC
212.265.9877
www.trimarkpublications.com/conferences/
###
MORE ARTICLES:
Spring Break Soccer Training and Spanish Language Camp in Puerto Vallarta, Mexico
Spring break soccer training and Spanish language camp will take place in Puerto Vallarta, Mexico.
More Vacations at Puerto Vallarta MX
Puerto Vallarta MX is definitely one of the places where people can stay and enjoy more vacations Puerto Vallarta MX is in the state of Jalisco and is one of Mexicoýs premier resort cities
Celebrate Grandparents at Grand Velas Resort in Puerto Vallarta
Dolphin Encounters, Spanish Lessons, Mexican Folkloric Night and More
As part of the Grandparents Package Available Until October 1st
Uncovered: A New Resource for Real Estate Investment Opportunities in Puerto Vallarta, Mexico
fundVallarta announces a full online resource for discovering real estate investment opportunities in Puerto Vallarta, Mexico. With conditions similar to the property boom in California, Puerto Vallarta is poised to become an international performer with a solid return on investment. Visitors are able to access a significant knowledge-based investment resource center at the fundVallarta.com website.
The Southern Pacific Coast has Snatched the Attention of Investors from the Northern Pacific Coast
There are so many wonderful things abouth Costa Rica's Southern Pacific coast. Each city has its own unique attractions that have really sparked interest with investors who see the vision and want to be part of the growth in Costa Rica.
Post-Holiday Spa Week and Duchess Detox in Mexico's Riviera Maya
Seven Day Mayan Retreat Package Available Through December 31, 2009 at Esencia Estate
Discount Last Minute Puerto Vallarta Packages To The Four Seasons Resort Punta Mita
We managed a discount last minute Puerto Vallarta package to the Four Seasons Resort Punta Mita. In truth the discount was the bonus, because we fully intended to go there anyway, and pay the full price, but thanks to some work online, we got a huge discount. A quick thank you to The Vacation Bargain Finder, details of which can be found at http://www.worldwidevacationspots.com/pages/Vacation-Bargain-Finder.html
A Mexico Travel Special To The Mexico Caribbean Coast
A Great Mexico Travel Special should include time spent on the Mexico Caribbean Coast, where you will find so much to do and so many things to enjoy. You can easily organise a Mexico Vacation Package that will allow you to travel around Mexico seeing some of the Country?s amazing sights and then allow you to finish with a relaxing time on the Mexico Caribbean Coast.
In-Suite Spa Treatments Exude Romance in Puerto Vallarta, Mexico
New In-Suite Spa Treament and Diamond Bath for Couples at Grand Velas All Suites & Spa Resort
The Beaches Of Puerto Vallarta
The beaches in and around Puerto Vallarta may be the most diverse in Mexico. Located at the midpoint of Banderas Bay, the area surrounding Puerto Vallarta boasts 34 miles of coastline, 26 of which are sandy beaches. Within the city, the beaches are elegant and pristine, bordered by restaurants and resorts. Beaches to the north of the city tend to be longer and wider, with great opportunities for surfing and swimming. South of Puerto Vallarta, the mountains topple into the sea in places, creating placid coves and intimate sandy pockets.
Resort in Mexico's Riviera Maya Offers Luxury, Family Fun, and Culinary Excellence
A recently completed expansion provides all-inclusive getaway
at the Hotel Marina El Cid Spa & Beach Resort.
Casa Velas in Puerto Vallarta, Mexico Receives AAA Four Diamond Award
Casa Velas Hotel Boutique in Puerto Vallarta, Mexico, is again joining the ranks of AAA Four Diamond Award winners. Casa Velas is the only adults-only all-inclusive golf resort in Mexico to receive this AAA Four Diamond award.
A Mexico Vacation Special To The Maroma Resort In The Mayan Riviera
Some very good reasons for booking a Mexico vacation special and choosing the best of luxury hotels the Maroma Resort in the Mayan Riviera
Iconic Mexican Performers Take Flight In Puerto Vallarta
Every weekend in Puerto Vallarta, a group of famous Mexican performers take flight From a central location on the Malec?n ? Puerto Vallarta?s beloved boardwalk ? the Papantla Flyers dazzle visitors with six performances each Saturday and Sunday
Win a Luxury All-Inclusive Mexican Vacation for a Family of Four in Puerto Vallarta, Mexico
Family Scavenger Hunt Leads to 4-Day/3-Night Mexican Vacation at Grand Velas All Suites & Spa Resort
